Hillstar Bio Launches with $67 Million Series A Financing to Develop Next Wave of Precision Immunotherapies to Transform Autoimmune Treatment
Press Releases
Hillstar Bio  
March 25, 2025

Hillstar Bio Launches with $67 Million Series A Financing to Develop Next Wave of Precision Immunotherapies to Transform Autoimmune Treatment

Proceeds to fund advancement of the company's lead TRBV9 program through clinical proof-of-concept study in axial spondyloarthritis and progression of broader pipeline

logo salamanca press

Salamanca Press

Local & Social